Portfolio
Strategy
Team
News
Careers
Contact
Investor Login
Portfolio
Strategy
Team
News
Careers
Contact
Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Advisor to its Board and Chair of its R and D Committee
Read Article
News
2024
2023
Archive
Search news articles
January 18, 2017
BIRD ROCK BIO RECEIVES APPROVAL TO START FIRST IN HUMAN CLINICAL TRIAL FOR NAMACIZUMAB, ENTERS INTO AGREEMENT WITH GE HEALTHCARE
January 17, 2017
PULMATRIX DRUG CANDIDATE RECEIVES “QUALIFIED INFECTIOUS DISEASE PRODUCT” (QIDP) DESIGNATION FROM THE FDA
January 9, 2017
AUDENTES THERAPEUTICS PROVIDES FULL YEAR 2017 STRATEGIC OUTLOOK AND FINANCIAL GUIDANCE
January 5, 2017
ARVINAS APPOINTS DR. JOHN HOUSTON AS PRESIDENT OF RESEARCH AND DEVELOPMENT AND CHIEF SCIENTIFIC OFFICER
January 5, 2017
APREA THERAPEUTICS ANNOUNCES PRESENTATION AT THE 35TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE IN SAN FRANCISCO
December 12, 2016
FLEXION THERAPEUTICS SUBMITS NEW DRUG APPLICATION FOR ZILRETTA™ TO TREAT KNEE OSTEOARTHRITIS PAIN
December 12, 2016
ACHAOGEN ANNOUNCES POSITIVE RESULTS IN PHASE 3 CUTI AND CRE CLINICAL TRIALS OF PLAZOMICIN
December 12, 2016
ARVINAS PRESENTS DATA ON ORAL ESTROGEN RECEPTOR PROTAC DEGRADER AT 2016 SAN ANTONIO BREAST CANCER SYMPOSIUM
December 9, 2016
ARVINAS COLLABORATORS PRESENT DATA ON BET PROTAC DEGRADERS AT 2016 ASH ANNUAL MEETING
December 5, 2016
NOHLA THERAPEUTICS ANNOUNCES CLOSING OF $43.5M SERIES A FINANCING TO TRANSFORM STEM CELL TRANSPLANTATION WITH INNOVATIVE OFF THE SHELF, UNIVERSAL DONOR CELLULAR THERAPY
« Previous Page
1
…
73
74
75
76
77
…
103